Fairvalue-Calculator Fairvalue-Calculator

Jiangsu Yuyue Medical Equipment & Supply Co (002223) Fair Value & Analysis

Healthcare · CN · Market cap 25.7B CNY

Price¥25.17
Fair Value¥32.01
Upside+27.2%
Quality94/100
Evidence: High Range ¥21.19 – ¥38.37

Analysis

Jiangsu Yuyue Medical Equipment & Supply Co (002223) currently trades at ¥25.17, while our model-based Fair Value estimate is ¥32.01 — implying the stock looks roughly 27.2% undervalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. provides medical devices and health product in China and internationally. It offers respiratory solutions, including PAP therapy, oxygen concentrators, nebulizers, high flow oxygen therapy, and airway clearances; diabetes management solutions; medical diagnostic devices, such as blood pressure monitors, oximeters, and thermometers; wheelchairs; AEDs; and traditional Chinese medicine product solutions. The company was formerly known as Yuwell medical. Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. was founded in 1998 and is based in Danyang, China.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABTT34) -20% Stryker Corporation (S1YK34) -45% Medtronic plc (MDT) -27% Boston Scientific Corporation (B1SX34) -5% Edwards Lifesciences Corporation (EW) -52% Siemens Healthineers AG (SEMHF) +11%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.